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SUMMARY 
From 1982 to 1989, pregnant women in two large city hospitals in The Netherlands had serum samples screened 
for hepatitis B surface antigen (HBsAg). Infants of mothers found to be HBsAg-positive received hepatitis B 
immune globulin immediately after birth and hepatitis B vaccine in the first year of life. Blood samples of infants 
were regularly tested for HBsAg and antibodies directed against HBsAg. A retrospective analysis of the pregnancy 
outcome in HBsAg-positive women who had invasive tests for prenatal diagnosis was carried out to determine 
whether amniocentesis and chorionic villus sampling (CVS) are risk factors for the intrauterine transmission of the 
hepatitis B virus. Amniocentesis was carried out in 17 HBsAg-positive women and C V S  in one case. Only two 
women were HBsAg- and HBeAg-positive. Prenatal diagnosis led to the termination of pregnancy for fetal 
chromosome abnormality in three cases. The remaining 15 pregnancies were uneventful, all infants were negative for 
HBsAg and developed an active immune response to the vaccine. These data suggest that amniocentesis in 
HBsAg-positive women constitutes a low risk for the intrauterine transmission of the hepatitis B virus, but definite 
conclusions in HBeAg-positive women cannot be drawn. 
KEY woms-Hepatitis B, amniocentesis, chorionic villus sampling, prenatal diagnosis, intrauterine infection, 
neonate. 
INTRODUCTION 
With increasing technical capabilities for more 
and earlier prenatal diagnosis, obstetricians should 
question the potential risks of invasive tests in 
hepatitis B surface antigen (HBsAg)-positive 
women. 
Without prophylactic measures, the risk of peri- 
natal infection among infants born to mothers 
infected with the hepatitis B virus (HBV) ranges 
from 10 to 90 per cent, depending on each 
mother’s hepatitis B e antigen (HBeAg) status 
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(Beasley et al., 1977; Stevens et al., 1979). Up to 
90 per cent of infants infected by their mothers 
at birth develop chronic HBV infection (Stevens 
et al., 1975). 
Most HBV infections occur perinatally; infants 
are exposed to the virus during labour (Stevens 
et al., 1975; Gerety and Schweitzer, 1977; Lee 
et al., 1978). Presumably mother-to-infant trans- 
mission occurs from haematological leaks across 
the placenta andor birth canal exposure to 
maternal secretions or blood (Beasley et a l ,  1982; 
Lin et a l ,  1987). 
Early administration of hepatitis B immune 
globulin (HBIg) to the newborn infant is therefore 
important to protect the infant from perinatal 
HBV infection. Passive-active immunization, con- 
sisting of HBIg and hepatitis B vaccine has been 
very effective (>90 per cent) in preventing HBV 
infection among infants born to HBsAg-positive 
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mothers (Stevens et al., 1987; Schalm e f  al., 1989). 
However, some HBeAg-positive mothers infect 
their infants before labour and delivery, i.e. during 
premature labour or threatened abortion (Ohto et 
al., 1987). These infants will not be amenable to 
immunoprophylaxis and any immunization pro- 
gramme is likely to fail. Hepatitis B virus is 
considered not to pass the intact placenta. Besides 
placental leakage due to uterine contractions, dis- 
ruption of the placental barriers may also result 
from invasive tests such as chorionic villus sam- 
pling (CVS) and amniocentesis for early prenatal 
diagnosis of fetal genetic disease. The question 
arises as to whether health-care professionals 
should offer an HBsAg-positive woman prenatal 
genetic testing where there is a chance of infecting 
the infant with HBV in utero. 
Because data in the literature are scarce, we 
retrospectively investigated the impact of early 
CVS and amniocentesis on intrauterine transmis- 
sions of HBV from HBsAg-positive women to 
their offspring. 
At the start of the vaccination programme, the 
potential risks of transmitting the hepatitis B virus 
through transplacental leakage caused by invasive 
diagnostic procedures were unknown. Since no 
records were kept on invasive testing for prenatal 
diagnosis in HBsAg-positive pregnant women, we 
performed a retrospective study of the files of 
HBsAg-positive women who had their newborn 
infants immunized within the trial. If prenatal 
genetic testing had been performed, this was 
followed by data collection on the sampling pro- 
cedure and pregnancy outcome. In addition, the 
HBV DNA levels of the HBsAg carrier mothers 
who had prenatal diagnosis performed were 
assayed quantitatively by HBV DNA assay 
(Abbott), since at present it is thought that the 
HBV DNA levels of the HBsAg carrier mothers 
are a better marker for infectivity than HBeAg 
(Lee et al., 1986). Intrauterine HBV infection was 
defined as the occurrence of HBsAg in cord blood 
and in the subsequent blood samples of infants. 
RESULTS 
PATIENTS AND METHODS 
In 1982 a multicentre trial was started in The 
Netherlands to detect HBsAg carrier mothers and 
to immunize their offpsring (Maze1 et al., 1984). 
Obstetricians in four treatment centres were asked 
to screen all pregnant women for HBsAg at the 
first antenatal visit. All confirmed HBsAg-positive 
samples were tested for HBeAg. The serum 
samples were assayed by radioimmunoassay 
(Abbott Laboratories, Chicago, IL). 
Infants of HBsAg-positive mothers who agreed 
to passive-active immunization of their new- 
borns received HBIg (100-150 IU anti-HBs/ml or 
300 IU anti-HBs/ml, Central Laboratory of the 
Netherlands Red Cross Blood Transfusion Service) 
at birth and active immunization according to 
several dose and time schedules. Cord blood and 
blood samples from infants were regularly tested 
for HBsAg (Ausria 11, Abbott) and anti-HBs 
(Ausab, Abbott) until at least 12 months of age. 
Three hundred and two HBsAg-positive women 
were identified and delivered over a 7-year period 
in the two university hospitals participating in the 
vaccination trial. Both hospitals act as centres for 
prenatal diagnosis. Amniocentesis or CVS is 
offered to women of advanced maternal age (2 36 
years) or with a history of fetal chromosomal 
anomaly or neural tube defects. 
Invasive prenatal diagnosis was carried out in 18 
of the 302 women found to be HBsAg-positive. Of 
40 HBsAg-positive women aged 36 years or older, 
only six (15 per cent) had undergone prenatal 
diagnosis. In another two women aged over 36 
years, prenatal diagnosis was not carried out 
because they were HBsAg-positive. In the other 
12 women, prenatal diagnosis was performed for 
reasons other than maternal age. Of the 18 
HBsAg-positive women, two were also HBeAg- 
positive. One HBeAg-positive woman had high 
levels of HBV DNA (61 pg/xnl). The other HBeAg- 
positive woman had an acute HBV infection at the 
time that she underwent prenatal diagnosis but her 
blood sample was not available for additional 
HBV DNA testing. All other women were HBV 
DNA-negative. 
Amniocentesis was performed in 17 cases and 
CVS in the remaining case. Indications for prena- 
tal diagnosis, HBeAg status of the women, mater- 
nal and gestational age, and pregnancy outcome 
are presented in Table I. Amniocentesis was per- 
formed at 154-18 weeks’ gestation; one woman, 
however, underwent amniocentesis at 30 weeks’ 
gestation because multiple malformations were 
identified by ultrasound. CVS was performed at 10 
weeks’ gestation. No transplacental amniocentesis 
was performed and the liquor samples showed no 
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Table I-Characteristics of the HBsAg-positive women and the prenatal procedures 
camed out 
~ 
Amniocentesis*, n= 17 (%) Chorionic villus sampling, n= 1 
Indication 
Maternal age 
Other 
HBeAg status 
HBeAg-positive 
HBeAg-negative 
Unknown 
Duration of gestation 
First trimester 
Second trimester 
Third trimester 
Pregnancy outcome 
Termination 
Liveborn 
6 (35.3) 
11 (64.7) 
2 (11.8) 
13 (76.4) 
2 (11.8) 
- 
16 
1 
3 (1 7.6) 
14 (82.4) 
*Not transplacental. 
signs of blood staining. The woman who had an 
acute hepatitis B infection and was both HBsAg- 
and HBeAg-positive at the time of amniocentesis 
displayed a low degree HBsAg-positive liquor (van 
0 s  et al., 1991). In all other cases, amniotic fluid 
was not tested for HBsAg. 
The pregnancy was terminated in three cases 
because of anencephaly (14.6 weeks) or multiple 
malformations (18.4 and 31 weeks). These women 
were all HBsAg-positive but HBeAg-negative. The 
remaining 15 pregnancies were uneventful and 
resulted in the delivery of 15 healthy infants. The 
mean gestational age for livebirths was 39.1 f 2-3 
weeks (range 32-42 weeks). The median birth 
weight was 3558 f 722.6 g (range 16604920 g). 
None of the neonatal blood samples was HBsAg- 
positive (0/15; 95 per cent confidence interval 
0-214). All infants were HBsAg-negative at the 
age of 3 months and thereafter. At the age of 12 
months, they had developed protective levels of 
anti-HBs following active immunization. 
DISCUSSION 
We have presented the outcome of invasive 
prenatal diagnosis in 15 women who were HBsAg- 
positive at the time of the procedure. All women, 
including those highly infective during invasive 
testing, gave birth to a healthy infant without signs 
of intrauterine HBV infection. HBsAg positivity 
within the first months of life despite immuno- 
prophylaxis at birth may be due to infection 
acquired in utero (Ohto et al., 1987). The patient 
population, however, was selected and numbers 
may be too small to declare invasive prenatal 
diagnosis in HBsAg-positive women completely 
safe. The upper unit of the 95 per cent confidence 
limit on a stroke rate of 0 per cent among 15 
patients is 22 per cent. 
The exact mode of intrauterine transmission of 
HBV from the mother to the infant is unknown. In 
cases of invasive testing involving the chorion or 
the placenta, HBV may be directly transmitted 
from maternal to fetal blood. Another possible 
route of HBV transmission may be the swallowing 
of HBsAg-contaminated amniotic fluid by the 
fetus. So, on a theoretical basis it seems safe to 
avoid transplacental procedures and/or CVS in 
HBsAg carrier pregnant women and certainly in 
the more infectious subgroup which is also 
HBeAg-positive or has high levels of HBV DNA. 
Any vascular area in the uterine wall should be 
avoided so as to limit the contamination,of the 
amniotic cavity with maternal blood. 
Several important factors associated with 
maternal-fetal transmissions of HBV need further 
discussion. A likely explanation for the absence of 
HBV infections in our study is that direct blood to 
blood contact did not take place. By comparison, 
HBV transmission by needle-stick has been shown 
to vary between 5 and 11 per cent (Grady et al., 
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1978; Seeff et al., 1978). The risk of infection 
depends on the level of infectivity of the injected 
material (Alter et al., 1976). After a percutaneous 
exposure to HBeAg-positive blood, the risk of 
transmission increases to approximately 30 per 
cent (Grady et al., 1978; Seeff et al., 1978). Since 
only two women may be considered as highly 
infective, the risk for the development of HBV 
infection through microleakage of maternal blood 
after invasive prenatal diagnostic techniques may 
have been negligible. The only woman who under- 
went CVS was HBeAg-negative, so no conclusions 
can be drawn on the safety of this procedure in 
HBeAg-positive women. 
Wong et al. (1980) performed third-trimester 
amniocentesis in 6 1 HBsAg-positive women and 
found HBsAg in 16 (26 per cent) liquor samples. 
Amniocentesis in HBsAg-positive women did not 
affect the incidence of HBsAg in 1-month-old 
babies (14.3 per cent), in comparison with a con- 
trol group (5 per cent) who did not have amnio- 
centesis ( D O .  1). However, a positive correlation 
(P=0.04) was reported in HBeAg-positive mothers 
between the presence of HBsAg in amniotic fluid 
and the finding of antigen in newborns at the age 
of 1 month. The authors concluded that amniocen- 
tesis should be discouraged if mothers are HBsAg- 
and HBeAg-positive. 
The risk of infection also depends on the quan- 
tity of injected material. Introduction of an 
amount as small as 10-*ml of HBeAg-positive 
blood is sufEicient for infection (Shikata et al., 
1977). The incidence of maternal-fetal transfusion 
in the literature varies from 2 to over 50 per cent, 
depending on complications during pregnancy and 
the methods of testing used (Schroder, 1975). The 
overall risk of fetal red cells entering the maternal 
circulation following amniocentesis was 10 per 
cent according to Sebring and Polesky (1990), and 
considerable fetal-maternal haemorrhage after 
CVS was described by Mantingh (1988), who 
found increased concentrations of maternal serum 
alpha-fetoprotein in 60 per cent of the blood 
samples. The degree of maternal-fetal transfusion 
and disruption of placental barriers as a result of 
invasive testing for prenatal diagnosis, however, is 
not known. 
Transmission of HBV by the oral route has been 
documented in an experimental setting but 
appeared far less effective than the parenteral route 
(Krugman and Giles, 1970). In the natural situa- 
tion, the risk of infection is considered to be very 
low. This finding is partly based on experience in 
endoscopy; HBV infection through endoscopy 
appeared low or non-existent (Villa et al., 1984). 
As 20 per cent of placental perforations are 
associated with bloody taps (Kappel et al., 1987), 
ingestion of HBsAg-contaminated amniotic fluid 
by the fetus is therefore not likely to be an im- 
portant mode of transmission. However, trans- 
placental procedures were not performed in our 
HBsAg-positive women. In the one woman who 
had weakly HBsAg-positive amniotic fluid, con- 
tamination with maternal blood is the most likely 
explanation. 
Finally, it is suggested that the fetal organs only 
become susceptible to HBV during the third tri- 
mester of pregnancy (Gerety and Schweitzer, 
1977). The risk of the hepatitis B virus being 
transmitted from a freshly infected mother to her 
fetus was 70 per cent during the third trimester, 
but appeared to be virtually non-existent in women 
who were infected at an earlier stage (Schweitzer, 
1975). Failure to transmit HBV from the mother 
to the fetus before the third trimester may be due 
to failure of the HBV to pass the placenta or 
failure of the fetus to support the HBV. For 
instance, no integration of HBV DNA was 
detected in fetal liver cells from 48 terminated 
pregnancies after 20-32 weeks of gestation (Li et 
al., 1986). Also, conception and development of 
the pre-embryo in an HBsAg-positive woman 
occur in a potentially infectious medium, and even 
the accidental HBV exposure of pre-embryos to a 
contaminated culture medium during in vitro fer- 
tilization procedures did not result in intrauterine 
infections (van 0 s  et al., 1991). 
Although data are scarce, the available informa- 
tion may support the idea that HBV will not harm 
the fetal liver early in pregnancy. The present 
uncertainties, however, point to the need for a 
more careful and considered approach to the wide- 
spread use of invasive prenatal diagnostic tech- 
niques in HBsAg-positive women. For highly 
infectious women (HBeAg-positive or HBV DNA- 
positive), a firm conclusion on the safety of inva- 
sive prenatal diagnosis, especially CVS, cannot be 
drawn. Perhaps, extensive studies in countries with 
a high prevalence of HBV may solve some of these 
issues. 
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